Immucell (ICCC) EBIT (2010 - 2026)

Immucell (ICCC) has reported EBIT for 17 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 239.72% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $2.5 million (up 42.28% YoY), and the FY2025 full-year result was $1.6 million, up 200.56% from the prior year.
• EBIT climbed to $1.9 million in Q2 2026 per ICCC's latest filing, from -$57956.0 in the prior quarter.
• Across five years, EBIT topped out at $1.9 million in Q2 2026 and bottomed at -$2.3 million in Q1 2023.
• Historically, EBIT has averaged -$318715.1 across 5 years, with a median of -$437473.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: EBIT sank 1223.53% in 2022, then soared 472.48% in 2025.
• Over 5 years, EBIT stood at -$1.6 million in 2022, then increased by 27.53% to -$1.2 million in 2023, then soared by 152.48% to $621395.0 in 2024, then slumped by 109.33% to -$57956.0 in 2025, then jumped by 3438.63% to $1.9 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $1.9 million, -$57956.0, and $20075.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.